Drug Profile


Alternative Names: Isoquercetin; Q Force; QB3C; QU995; Quercetin-3-O-glucoside

Latest Information Update: 22 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Beijing Chemical Reagent Factory; Catholic University of the Sacred Heart - Rome; Farr Laboratories LLC; Indiana University School of Medicine; Quercegen Pharmaceuticals; Singapore General Hospital; SRI International; Taiyuan Pharmaceutical Factory; University of Birmingham; University of California at Los Angeles; University of Ulster
  • Developer Dana-Farber Cancer Institute; National Institutes of Health (USA); Quercegen Pharmaceuticals; University of Michigan
  • Class Flavonoids; Small molecules
  • Mechanism of Action Antioxidants; Enzyme inhibitors; Free radical scavengers; Platelet aggregation inhibitors; Prostaglandin synthase stimulants; Protein tyrosine kinase inhibitors; Thromboxane A2 synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Thromboembolism
  • Phase I/II Chronic obstructive pulmonary disease
  • Discontinued Atherosclerosis; Cancer; Cardiovascular disorders; Prostatitis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 22 Jan 2018 Quercetin is still in phase II/III trials for Thromboembolism (Prevention) in USA (PO) (NCT02195232)
  • 08 Dec 2016 M. D. Anderson Cancer Center plans a phase 0 trial for Chemotherapy induced neuropathic pain in USA (NCT02989129)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top